Biosimilars: Opinion of an expert panel in the Middle East

Current Medical Research and Opinion

Volumn 24, Issue 10, 2008, Pages 2897-2903

  Bohlega, Saeed ^a   Al Shammri, S ^b   Al Sharoqi, I ^c   Dahdaleh, M ^d   Gebeily, S ^e   Inshasi, J ^f   Khalifa, A ^g   Pakdaman, H ^h   Szolics M ⁱ   Yamout, B ^j  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b KUWAIT UNIVERSITY   (Kuwait)

^c SALMANIYA MEDICAL COMPLEX   (Bahrain)

^d Arab Medical Centre   (Jordan)

^e Dep of Physics and Electronics   (Lebanon)

^f RASHID HOSPITAL   (United Arab Emirates)

^g Damascus Hospital   (Syrian Arab Republic)

^h SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

more..

Author keywords

Biosimilars; Biotechnology derived; Guidelines; Immunogenicity; Interchangeabilty; Registration; Substitution

Indexed keywords

ABSEAMED; ALPHA2A INTERFERON; ALPHEON; BETA1A INTERFERON; BINOCRIT; BIOLOGICAL PRODUCT; BIOSIMILAR PRODUCT; CINNAGEN; CINNOVEX; EPOIETIN ALFA HEXAL; ERYPRO; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; HUMAN INSULIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ARTICLE; BIOTECHNOLOGY; CLINICAL TRIAL; CONSENSUS; DRUG APPROVAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; DRUG STORAGE; EUROPE; HUMAN; IMMUNOGENICITY; INFORMATION RETRIEVAL; MIDDLE EAST; PATENT; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; QUALITY CONTROL; REGISTRATION; UNITED STATES; UNSPECIFIED SIDE EFFECT;

BIOMIMETIC MATERIALS; BIOMIMETICS; GUIDELINES AS TOPIC; HUMANS; INVESTIGATIONAL NEW DRUG APPLICATION; MIDDLE EAST;

EID: 55549146824     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802381554     Document Type: Article

References (14)

1. Schellekens H. Follow-on biologics: challenges of the 'next generation'. Nephrol Dial Transplant 2005;20(Suppl 4):iv31-iv36
2. EGA. Frequently asked questions about generic medicines. 2007; Available at www.egagenerics.com/FAQ-generics.htm [last accessed 5 March 2008]
3. EMEA. Questions and answers on generic medicines. EMEA Document EMEA/ 393905/2006 April 2007. Available at www.emea.europa.eu/pdfs/buman/pcwp/ 39390506en.pdf [last accessed 24 July 2008]
4. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-19
5. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007;30:267-72
6. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v4-v8
7. Hepner F, Csaszar E, Roitinger E, et al. Mass spectrometrical analysis of recombinant human growth hormone Norditropin reveals amino acid exchange at M14_V14 rhGH. Proteomics 2006;6:775-84
8. Hepner F, Cszasar E, Roitinger E, et al. Mass spectrometrical analysis of recombinant human growth hormone (Genotropin(R)) reveals amino acid substitutions in 2% of the expressed protein. Proteome Sci 2005;3:1
9. Hokke CH, Bergwerff AA, van Dedem GW, et al. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett 1990;275:9-14
10. Hubbard SC, Walls L, Ruley HE, et al. Generation of Chinese hamster ovary cell glycosylation mutants by retroviral insertional mutagenesis. Integration into a discrete locus generates mutants expressing high levels of N-glycolylneuraminic acid. J Biol Chem 1994;269:3717-24
11. Martin MJ, Muotri A, Gage F, et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005;11:228-32
12. EMEA. Questions and answers on biosimilar medicines (similar biological medicinal products). EMEA Document EMEA/74562/2006 June 2007. Available at www.emea.europa.eu/pdfs/human/pcwp/7456206en.pdf [last accessed 24 July 2008]
13. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21(Suppl 5):v13-v6
14. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals, Nephrol Dial Transplant 2006; 21(Suppl 5):v9-vl2